Satavaptan in the Prevention of Ascited Recurrence: A Double-Blind, Randomized, Parallel-Group Comparison of 12 Weeks Treatment with SR121463B at 5 to 10 mg Daily Versus Placebo in Patients with Recurrent Ascited due to Cirrhosis of the Liver